Business
Cytophage Launches Incubator Egg Trials for OvaPhage in Partnership with Leading Canadian Hatchery
(TheNewswire) WINNIPEG, MB – February 5, 2025 – TheNewswire - Cyt...
About this update from Cytophage Technologies Ltd.
[{"type":"text","content":"Cytophage Launches Incubator Egg Trials for OvaPhage in Partnership with Leading Canadian Hatchery \n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n WINNIPEG, MB – February 5,\n2025\n \n\n –\n \n\n TheNewswire -\n \n\n Cytophage Technologies (‘Cytophage’ or\n‘the Company’) (TSXV: CYTO; FSE: 70G) is proud to announce a new\npartnership with one of Canada’s leading poultry hatcheries to begin\nincubator egg trials for OvaPhage, an innovative bacteriophage product\ndesigned to only target harmful bacteria on the surface of eggs, while\npreserving the natural protective cuticle of eggs. The trials are\nexpected to be completed by the third quarter of this year, and are\nthe next steps in proving the efficacy of OvaPhage. Cytophage’s\nearly lab tests have demonstrated a 99% reduction in bacterial load on\nthe surface of eggs, setting the stage for this critical new phase of\nreal-world validation.\n \n\n\n\n Upon completion of the trials, Cytophage plans to\nprepare regulatory submissions, paving the way for OvaPhage’s\ninitial market launch in Canada, with global expansion to\nfollow.\n \n\n\n\n There are over 200 hatching egg producers in Canada. In\n2023, hatching egg farmers produced approximately 868 million broiler\nhatching eggs\n \n\n\n\n according to the\nCanadian Hatching Egg Producers\n \n\n\n\n ,\ngenerating $500 million in farm revenues. Cytophage’s partner\nhatchery represents a key segment of this market, and is recognized as\na leader in advanced poultry management systems. The hatchery’s\nstaff are working closely with Cytophage to improve resiliency and\nproductivity in the poultry industry. OvaPhage addresses key industry\npriorities, such as reducing bacterial contamination and increasing\nhatch rates.\n \n\n\n\n “This moment marks a turning point for our company.\nMoving from the lab to incubator egg trials is a key milestone in\nproving OvaPhage’s real-world efficacy,” said Cytophage CEO Dr.\nSteven Theriault. “We are excited to demonstrate how this technology\ncan redefine standards for the industry.”\n \n\n\n\n OvaPhage Trials Process\n \n\n\n\n The OvaPhage trials advance in three stages, each one\nmoving the product towards broader commercialization:\n \n\n\n\n\n...